<DOC>
	<DOCNO>NCT00616889</DOCNO>
	<brief_summary>Clinical practice indicate Quetiapine sedate property , sedative effect may play important role restore quality sleep patient various psychiatric condition frequently experience sleep disturbance part illness . It well know depressive disorder frequently associate significant sleep disturbance . Sleep disruption feature Bipolar Disorder Depressed Manic/Hypomanic episode . Considering Seroquel good antidepressant property ( Calabrese , 2004 ) , investigator suggest Seroquel 's effect sleep architecture contribute antidepressant property .</brief_summary>
	<brief_title>Effect Quetiapine Sleep Architecture Bipolar Depression Major Depressive Disorder</brief_title>
	<detailed_description>Primary Objective : To assess objective ( polysomnographic ) change sleep quality introduction Seroquel ( Quetiapine ) treatment patient Bipolar Depression Major Depressive Disorder . Secondary Objectives : To assess objective ( polysomnographic ) subjective change sleep quality parameter different stage introduction Seroquel ( Quetiapine ) treatment , longitudinally , correlate change measure illness severity . Study Design : Prospective polysomnographic ( PSG ) study patient treatment Seroquel ( Quetiapine ) . PSG record do three ( optional four ) time study : start Seroquel ( Quetiapine ) ( baseline ) , day 2 4 ( early ) day 21 28 ( long term ) . ( Optional fourth PSG do day 42-56 ) . PSG complete patient home portable PSG .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Provision write informed consent ; 2 . A diagnosis Bipolar Disorder Type 1,2 NOS Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) ; OR Major Depressive Disorder 3 . Males Females age 18 year ; 4 . Female patient childbearing potential must use reliable method contraception negative urine human chorionic gonadotropin ( HCG ) test enrolment ; 5 . Able understand comply requirement study ; 6 . Current depressive episode HAMD17 score 15 . 1 . Current Manic , Hypomanic Mixed episode , YMRS 12 ; 2 . Current past diagnosis Schizophrenia ; 3 . Pregnant woman , woman childbearing age , willing use appropriate contraception woman currently nurse ; 4 . Patient antipsychotic medication ; 5 . Patients , opinion investigator , pose imminent risk suicide danger self others ; 6 . Known intolerance lack response quetiapine fumarate , judge investigator ; 7 . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir ; 8 . Use follow cytochrome P450 inducer 14 day precede enrolment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid ; 9 . Administration depot antipsychotic injection within one dose interval ( depot ) randomization ; 10 . Substance alcohol dependence enrolment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion ; 11 . Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen dependence DSMIV criterion within 4 week prior enrolment ; 12 . Medical condition would affect absorption , distribution , metabolism , excretion study treatment ; 13 . Unstable inadequately treat medical illness ( e.g. , diabetes , angina pectoris , hypertension ) judge investigator ; 14 . Involvement plan conduct study ; 15 . Previous enrolment present study ; 16 . Participation another drug trial within 4 week prior enrolment study long accordance local requirement ; 17 . If participant 's liver function test rat 2 upper limit normal . 18 . Diagnosis Dementia 19 . Regular use benzodiazepine unless stable dose least 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>